Leishmania infantum paraflagellar rod proteins antibody and antigen (recombinant protein)

Diagnostic anti-Leishmania infantum paraflagellar rod proteins antibodies pairs and antigen for animal health (animal Dog/Canine infectious disease visceral leishmaniasis) testing in ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA and POCT

Target products collectionGo to Companion Animal disease testing products collection >>


Product information

Catalog No. Description US $ Price (per mg)
GMP-VT-P023-Tg002-Ag01 Recombinant Leishmania infantum paraflagellar rod proteins protein $3090.00
GMP-VT-P023-Tg002-Ab01 Anti-Leishmania infantum paraflagellar rod proteins mouse monoclonal antibody (mAb) $3090.00
GMP-VT-P023-Tg002-Ab02 Anti-Leishmania infantum paraflagellar rod proteins mouse monoclonal antibody (mAb) $3090.00
GMP-VT-P023-Tg002-Ab03 Anti-Leishmania infantum paraflagellar rod proteins human monoclonal antibody (mAb) $3090.00
GMP-VT-P023-Tg002-Ab04 Anti-Leishmania infantum paraflagellar rod proteins human monoclonal antibody (mAb) $3090.00

Size: 1mg | 10mg | 100mg



Product Description

Cat No. GMP-VT-P023-Tg002-Ag01
Product Name Recombinant Leishmania infantum paraflagellar rod proteins protein
Pathogen Leishmania infantum
Expression platform E.coli
Isotypes Recombinant Antigen
Bioactivity validation Anti-Leishmania infantum paraflagellar rod proteins antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in Leishmania infantum level test of animal Dog/Canine infectious disease with visceral leishmaniasis.
Tag His
Product description Recombinant Leishmania infantum paraflagellar rod proteins proteinwas expressed in E.coli - based prokaryotic cell expression system and is expressed with 6 HIS tag at the C-terminus.
Purity Purity: ≥95% (SDS-PAGE)
Application Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
Formulation Lyophilized from sterile PBS, PH 7.4
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.


Cat No. GMP-VT-P023-Tg002-Ab01,GMP-VT-P023-Tg002-Ab02
Pathogen Leishmania infantum
Product Name Anti-Leishmania infantum paraflagellar rod proteins mouse monoclonal antibody (mAb)
Expression platform CHO
Isotypes Mouse IgG
Bioactivity validation Recombinant Leishmania infantum paraflagellar rod proteins antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Leishmania infantum antibodies in Leishmania infantum level test of animal Dog/Canine infectious disease with visceral leishmaniasis.
Product description Anti-Leishmania infantum paraflagellar rod proteins mouse monoclonal antibody (mAb) is a mouse monoclonal antibody produced by CHO technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Leishmania infantum antibodies.
Purity Purity: ≥95% (SDS-PAGE)
Application Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
Formulation Lyophilized from sterile PBS, PH 7.4
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.


Cat No. GMP-VT-P023-Tg002-Ab03,GMP-VT-P023-Tg002-Ab04
Pathogen Leishmania infantum
Product Name Anti-Leishmania infantum paraflagellar rod proteins human monoclonal antibody (mAb)
Expression platform CHO
Isotypes Human lgG1
Bioactivity validation Recombinant Leishmania infantum paraflagellar rod proteins antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Leishmania infantum antibodies in Leishmania infantum level test of animal Dog/Canine infectious disease with visceral leishmaniasis.
Product description Anti-Leishmania infantum paraflagellar rod proteins mouse monoclonal antibody (mAb) is a human monoclonal antibody produced by CHO. The antibody is ELISA validated as capture antibody and detection antibody pair.
Purity Purity: ≥95% (SDS-PAGE)
Application Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
Formulation Lyophilized from sterile PBS, PH 7.4
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.


Reference




    Validation Data


    Click to get more Data / Case study about the product.



    Pathogen Information


    Leishmania infantum is a species of the genus Leishmania belonging to the Trypanosomatidae family. This protozoan parasite is responsible for causing a disease called visceral leishmaniasis (VL), also known as Kala-azar, in humans and dogs. VL affects the internal organs such as liver, spleen, and bone marrow, and it is one of the most severe forms of leishmaniasis. Other names for this parasite include L. infantum, Leishmania chagasi, and Mediterranean visceral leishmaniasis.

    Leishmania infantum is a eukaryotic organism, meaning it has membrane-bound organelles, including a nucleus that contains its genetic information, and other specialized cellular structures. The genome of Leishmania infantum is fully sequenced, and it consists of approximately 35 Mb of haploid DNA distributed among 36 chromosomes. The genome encodes around 8,300 protein-coding genes, some of which are shared among different Leishmania species.

    The pathogenesis of Leishmania infantum involves a complex mechanism of interaction between the parasite and the host's immune system. The parasite’s life cycle consists of two main stages: promastigotes and amastigotes. Promastigotes are the extracellular forms of the parasite found within the midgut of the sandfly vector. They differentiate into amastigotes when they enter the host's phagocytic cells. Amastigotes are the intracellular forms of the parasite, which replicate within the phagolysosomal compartments of macrophages.

    Leishmania infantum possesses several genes and proteins that allow it to survive and evade the host's immune system. For instance, heat shock proteins (HSPs) help in protein folding and stress response, while amastigote-specific A2 protein (ASP) promotes persistency of the parasite within the host's cells. Cysteine Protease B (CPB) and surface metalloprotease GP63 are among the main proteases identified in this pathogen that degrade host immune factors like immunoglobulins, complement proteins and cytokines, which are crucial for the host's defense mechanisms.

    Dogs are considered the primary hosts for Leishmania infantum. However, humans can also become infected by the bite of an infected sandfly, leading to visceral or cutaneous leishmaniasis. Visceral leishmaniasis is characterized by fever, fatigue, and an enlarged spleen and liver, among other symptoms. Cutaneous leishmaniasis typically presents as a lesion on the skin or mucous membrane.

    To diagnose leishmaniasis caused by Leishmania infantum, various techniques exist, including microscopic examination of tissue samples, serological tests, polymerase chain reaction (PCR), and loop-mediated isothermal amplification (LAMP). These diagnostic methods aim to detect the presence of the parasite's DNA or RNA within the patient's sample. They often target specific regions of the genome, such as kinetoplast DNA (kDNA), 18S ribosomal RNA (rRNA) gene, and internal transcribed spacer 1 (ITS1) region. Some diagnostic methods may focus on Leishmania infantum-specific proteins such as the kinesin-related protein (KRP), the recombinant kinesin antigen (rK39), and the rNIE protein, which are highly prevalent in infected individuals.

    In conclusion, Leishmania infantum is a parasitic protozoan organism that causes severe infections in humans and dogs. The pathogen possesses several genes and proteins that allow it to evade the host's immune system and persist within the host's cells. Although specific diagnostic tests exist, leishmaniasis remains a significant health problem in many parts of the world, and efforts are ongoing to develop more effective treatments and vaccines against this disease.



    About GDU


    GDU

    GDU helps global diagnostic partners in high quality of raw material discovery, development, and application. GDU believes in Protein&antibody Innovation for more reliable diagnostic solutions.